Association of the COMT val158met variant with antidepressant treatment response in major depression
Association of the COMT val158met variant with antidepressant treatment response in major depression
复制标题
DOI：
10.1038/sj.npp.1301462
复制
发表时间：
2008-03-01
影响因子：
7.6
通讯作者：
Domschke, Katharina
中科院分区：
文献类型：
--
作者：
Baune, Bernhard T.;Hohoff, Christa;Domschke, Katharina
在一些以前的生化，药理学和遗传学研究，儿茶酚-O-甲基转移酶（COMT）已被认为是参与的发病机制，以及情感障碍的药物治疗。在本研究中，256例白人后裔的抑郁症（DSM-IV）患者进行了基因分型的功能COMT val 158 met多态性，并通过6周内汉密尔顿抑郁症（HAM-D-21）评分的个体内变化来衡量抗抑郁药物治疗的临床反应。COMT 158瓦尔/瓦尔基因型在重度抑郁症患者中给予4-6周抗抑郁治疗后反应变差的显著风险（第4周：p = 0.003;第5周：p
In several previous biochemical, pharmacological, and genetic studies, the catechol-O-methyltransferase (COMT) has been suggested to be involved in the pathogenesis as well as the pharmacological treatment of affective disorders. In the present study, 256 patients with major depression (DSM-IV) of Caucasian descent were genotyped for the functional COMT val158met polymorphism and characterized for clinical response to antidepressive pharmacological treatment as measured by intra-individual changes of Hamilton Depression (HAM-D-21) scores over 6 weeks. The COMT 158val/val genotype conferred a significant risk of worse response after 4-6 weeks of antidepressant treatment in patients with major depression (week 4: p = 0.003; week 5: p